Methods for inducing protective immunity against human immunodeficiency virus infection
AssigneesJanssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc.
InventorsDan Barouch, Johanna Schuitemaker, Maria Grazia Pau, Danielle Van Manen, Frank Tomaka, Jennifer Anne Hendriks
Life of this patent
Estimating the term…
Abstract
Compositions, vaccines and methods for inducing protective immunity against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of HIV.
Claims27
A method of inducing an immune response against a human immunodeficiency virus (HIV) in a subject, the method comprising:
- (i) administering to the subject a primer composition comprising an immunogenically effective amount of one or more adenovirus 26 (rAd26) vectors encoding one or more HIV antigenic polypeptides comprising amino acid sequences selected from the group consisting of SEQ ID NOs:
- 1-4, respectively, and a pharmaceutically acceptable carrier;
- and
- (ii) administering to the subject a first booster composition comprising an immunogenically effective amount of an isolated HIV envelope polypeptide comprising at least one of a stabilized trimer of HIV gp140 comprising the amino acid sequence of SEQ ID NO:
- 5 and a stabilized trimer of HIV gp140 comprising the amino acid sequence of SEQ ID NO:
- 6, and a pharmaceutically acceptable carrier;
- and
- (iii) administering to the subject a second booster composition together with the first booster composition, the second booster composition comprising an immunogenically effective amount of one or more additional adenovirus 26 (rAd26) vectors encoding one or more additional HIV antigenic polypeptides comprising amino acid sequences selected from the group consisting of SEQ ID NOs:
- 1-4, respectively, and a pharmaceutically acceptable carrier;
- wherein the first and second booster compositions are administered after the primer vaccine is administered.
A method of inducing an immune response against a human immunodeficiency virus (HIV) in a subject, the method comprising:
- (i) administering to the subject a primer composition comprising an immunogenically effective amount of one or more adenovirus 26 (rAd26) vectors encoding HIV antigenic polypeptides having the amino acid sequences of SEQ ID NO:
- 1, SEQ ID NO:
- 3, and SEQ ID NO:
- 4, respectively, and a pharmaceutically acceptable carrier;
- and
- (ii) administering to the subject a first booster composition comprising an immunogenically effective amount of an isolated HIV envelope polypeptide comprising a stabilized trimer of HIV gp140 having the amino acid sequence of SEQ ID NO:
- 5, and a pharmaceutically acceptable carrier;
- and
- (iii) administering to the subject a second booster composition together with the first booster composition, the second booster composition comprising an immunogenically effective amount of one or more additional rAd26 vectors encoding HIV antigenic polypeptides having the amino acid sequences of SEQ ID NO:
- 1, SEQ ID NO:
- 3, and SEQ ID NO:
- 4, respectively, and a pharmaceutically acceptable carrier;
- wherein the first and second booster compositions are administered after the primer vaccine is administered.
Dependencies are inferred from the claim text.